Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:27:42 EDT Fri 11 Jul 2025
Enter Symbol
or Name
USA
CA



Q:VSTM - VERASTEM INC - https://www.verastem.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VSTM - Q0.24.60·5.727.04.685-0.055-1.21,212.95,2985,9824.72  4.75  4.589.10  2.1019:56:2116:1215 min RT 2¢

Recent Trades - Last 10 of 5982
Time ETExPriceChangeVolume
19:56:21Q4.770.0372
19:48:20Q4.78860.0486500
19:44:23Q4.790.054
19:40:35Q4.78920.049228
19:37:23Q4.790.0570
19:34:43Q4.790.054
19:30:03Q4.780.04500
19:29:32Q4.790.0510
19:14:03Q4.78830.048350
19:07:38Q4.72-0.025

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-11 16:12U:VSTMNews ReleaseVerastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology
2025-07-08 08:50U:VSTMNews ReleaseGlobal Oncology Breakthroughs Being Fueled by Advancements in Clinical Trials and New Therapies
2025-07-08 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-06-30 16:02U:VSTMNews ReleaseVerastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer
2025-06-24 16:02U:VSTMNews ReleaseVerastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors
2025-06-02 09:40U:VSTMNews ReleaseVerastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor
2025-05-28 07:30U:VSTMNews ReleaseVerastem Oncology to Present at the Jefferies Global Healthcare Conference
2025-05-22 17:01U:VSTMNews ReleaseVerastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma
2025-05-13 16:34U:VSTMNews ReleaseVerastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates
2025-05-08 13:17U:VSTMNews ReleaseFDA Approves the AVMAPKI(TM) FAKZYNJA(TM) Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer
2025-05-01 07:30U:VSTMNews ReleaseVerastem Oncology to Present at Upcoming Investor Conferences
2025-04-25 09:00U:VSTMNews ReleaseVerastem Oncology Announces $75 million Private Placement
2025-04-23 16:05U:VSTMNews ReleaseVerastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors
2025-04-07 07:30U:VSTMNews ReleaseVerastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2025-03-25 16:35U:VSTMNews ReleaseVerastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025
2025-03-20 16:01U:VSTMNews ReleaseVerastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
2025-02-20 16:05U:VSTMNews ReleaseVerastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women's Cancer
2025-01-29 07:30U:VSTMNews ReleaseVerastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
2025-01-23 07:30U:VSTMNews ReleaseVerastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
2025-01-15 07:30U:VSTMNews ReleaseVerastem Oncology Names Matthew E. Ros as Chief Operating Officer